Nirmatrelvir-Ritonavir No Aid for Long COVID Symptoms
10 Jun 2024
Clinical ResultClinical Study
MONDAY, June 10, 2024 -- A 15-day course of nirmatrelvir-ritonavir (NMV/r) is safe but does not demonstrate a significant benefit for improving postacute sequelae of SARS-CoV-2 infection (PASC) symptoms, according to a study published online June 7 in JAMA Internal Medicine to coincide with the Demystifying Long COVID North American Conference 2024, held from June 6 to 7 in Boston.
Linda N. Geng, M.D., Ph.D., from the Stanford University School of Medicine in California, and colleagues assessed the efficacy of a 15-day course of NMV/r in reducing the severity of select PASC symptoms. The analysis included 155 adults with moderate-to-severe PASC symptoms (more than three months of duration) who were randomly assigned (2:1) to treatment with oral NMV/r (300 mg and 100 mg) or placebo-ritonavir (PBO/r) twice daily.
Nearly all participants (153 of 155) had received the primary series for COVID-19 vaccination, and the mean time between index SARS-CoV-2 infection and randomization was 17.5 months. At 10 weeks, the researchers observed no significant difference in the model-derived severity outcome pooled across the six core symptoms (fatigue, brain fog, shortness of breath, body aches, gastrointestinal symptoms, and cardiovascular symptoms) between the NMV/r and PBO/r groups. There were also no significant between-group differences seen for the Patient Global Impression of Severity or Patient Global Impression of Change scores, summative symptom scores, or change from baseline to 10 weeks in Patient-Reported Outcomes Measurement Information System fatigue, dyspnea, cognitive function, and physical function measures. Adverse event rates were mostly low grade and similar between the groups.
"Some studies suggest that viral particles and molecular debris could be responsible for some long COVID sufferers' ongoing symptoms," senior author Upinder Singh, M.D., also from Stanford University, said in a statement. "We figured if that's the case, maybe treating them with Paxlovid could relieve some of these symptoms."
The study was funded by Pfizer, the manufacturer of nirmatrelvir-ritonavir (Paxlovid).
Abstract/Full Text
More Information
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.